The company that was in FT1000 Top 3 of America’s fastest-growing companies in 2020 posted its first earnings figures since it hit the public market this April
became a publicly traded company this April, and yesterday after the market
closed, it reported revenue figures that topped consensus. For the fiscal first
quarter 2022, the company revealed that its revenue grew 65% to $186.2 million
from a year earlier and ahead of the $168.6 million expected. Under the Generally
Accepted Accounting Principles (GAAP), UiPath had a loss-per-share of $1.11.
The company also announced that its number of customers
topped 8,500, with 1,105 generating more than $100K and 104 over $1 million in
revenues per year.
For the fiscal second quarter of 2022, UiPath projects a revenue
as high as $185 million, a possible 33% increase from a year earlier. The
strong demand for its products would drive the surge.
UiPath closed yesterday’s trading session at $76 per share.
Find out more about the company’s IPO here!
Sources: marketwatch.com, seekingalpha.com
This information prepared by ClickTrades.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.
This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.
You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.
This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of ClickTrades.com.
Amgen's Lumakras approved by the FDA
McDonald’s South Korea and Taiwan operation got hacked